tbuckley/cabot-search huggingface dataset:
AB0615 Is there a relationship between the educational level and vertebral fractures in moroccan postmenopausal women?
Authors: L. Bouazzaoui, S. rostom, R. bahiri, F. allali, N. hajjaj hassouni
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> <h3>Objectives</h3> to assess the influence ofeducational level on the risk of vertebral fractures and its risk factors in postmenopausal women. <h3>Methods</h3> Cross-sectional studyincluding 276 postmenopausal women recruited from the bone densitometry center. The socio demographic, clinical and paraclinical parameters related to patients were collected. Patients were stratified according to the number of years of study into four groups according to the educational level: (Group 1: illiterate = 0 years of study), (group 2: primary &lt;5 years of study) (Group 3: High = 6-8 years of study), (group 4 academic ≥ 9 years studies). All the patients hadsystematically an evaluation of calcium, phosphate serum levels, and Bone mineral density. Two Lateral radiographs (thoracic and lumbar radiographs) and antero-posterior radiographs were performed in all patients. Vertebral fractures were defined using the Genant score. <h3>Results</h3> The mean age ofpatients was 59.01 ± 8.40 years. The median ageof menopausewas 49[45-50]. Twenty-six percent of patients were illiterate, 19% had a primary educational level, 38 4% secondary level and 17% university level. The prevalence of vertebral fractures was inversely correlated with educational level, ranging from36%for illiterateand 19%foruniversity level. In univariate analysis with logistic regression, there was an association between the presence of vertebral fractures and age, the age of menarche, thefemoral BMD and calcium intake (for all p &lt;0.05). In multivariate analysis, and using group 1 as the reference category, an increase in the educational level was associated with a reduced risk of vertebral fracture (secondary: OR = 0.33, 95% CI: 0.13-0.82, p = 0.01), (tertiary: OR = 0,31, 95% CI: 0.19-0.62, p = 0.04). <h3>Conclusions</h3> This studysuggests that low educational level is independently associated with low BMD and risk of vertebral fractures. Further studies are needed to verify these results. <h3>Disclosure of Interest</h3> None Declared
Abstract 4098: The HMGA1-COX-2 axis: A molecular pathway leading to tumor progression in human pancreatic adenocarcinoma
Authors: Joelle Hillion, Francescopaolo Di Cello, Shamyra Smail, Matthew Griffin, Leslie Cope, Anirban Maitra, David Huso, Linda Resar
Journal: Cancer Research (2010)

Abstract Pancreatic ductal adenocarcinoma is a highly lethal cancer accounting for over 160,000 deaths worldwide each year. Despite the high prevalence of pancreatic cancer, the molecular events that lead to tumor progression are poorly understood. The high-mobility group A1 gene (HMGA1) is enriched in diverse, high-grade cancers and embryonic stem cells. This gene encodes the HMGA1a and HMGA1b chromatin remodeling proteins, which function in regulating gene expression. We previously showed that HMGA1 induces oncogenic transformation in cultured cells and causes aggressive cancers in transgenic mice. Moreover, we found that high HMGA1 protein levels correlate with poor differentiation status and decreased survival in a study of &amp;gt; 100 primary pancreatic ductal adenocarcinomas. These findings suggest that HMGA1 could drive a poorly differentiated, stem cell-like state and tumor progression in pancreatic ductal adenocarcinoma. In cultured, human pancreatic cells that overexpress K-RAS (HPNE-K-RAS cells), forced overexpression of HMGA1a leads to increased migration, invasion, and a transformed phenotype with anchorage-independent cell growth in soft agar. Because cyclooxygenase-2 (COX-2) is a downstream gene directly activated by HMGA1a in uterine cancers, we investigated the role of the HMGA1-COX-2 pathway in pancreatic adenocarcinoma. Our preliminary data suggest that HMGA1a and COX-2 mRNA levels are positively correlated in a pancreatic cancer cell lines. By chromatin immunoprecipitation, we found that HMGA1a binds to the COX-2 promoter in human pancreatic adenocarcinoma cells. Moreover, COX-2 inhibitors block tumorigenesis in human pancreatic cancer xenografts in nude mice. Taken together, our studies suggest that HMGA1a promotes tumor progression through up-regulation of COX-2 and this pathway could be targeted to treat or prevent human pancreatic adenocarcinoma. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 4098.
PWE-181 The Development and Evolution of Nutrition Service Provision in the North East: 2003–2012
Authors: J H Adam, N Thompson
Journal: Gut (2013)

<h3>Introduction</h3> Malnutrition is well recognised as a treatable cause and result of ill-health. The recognition and management of malnutrition hinges upon the quality of organisation of nutrition services as well as the quality of the interventions themselves. Malnutrition is common amongst inpatients and decisions regarding management are often complex. The care of patients with complex nutritional needs can be optimised by combining the expertise of those from multiple allied disciplines. These principles are highlighted in the 2006 NICE guideline: Nutrition Support in Adults. This study analyses the progress made at an organisational level in providing nutrition services in hospitals across the North East of England, with reference to recommendations made by NICE. <h3>Methods</h3> Nutrition service provision was evaluated by distributing questionnaires to all acute hospitals in the North East region in 2003, 2007 and 2012. Questionnaires were completed by a dietician from each hospital. The questionnaire addressed the provision of Nutrition Support Teams. We analysed the representation of team members from different disciplines, frequency of meetings and topics discussed. We also sought qualitative and quantitative data regarding inpatient and outpatient use of Total Parenteral Nutrition (TPN), the use of malnutrition screening tools and access to obesity services. <h3>Results</h3> Response rates were 92% in 2003 and 100% in 2007 and 2012. Over 9 years the percentage of hospitals with Nutrition Support Teams has increased from 19% to 42%. Each team discusses an increasing number of patients as well evaluating and developing their local policies and procedures. In line with NICE recommendations, 100% of acute trusts have a Nutrition Steering Committee in 2012, rising from 31% in 2003 and 94% in 2007. The number of patients able to access inpatient TPN has increased across the region whilst the provision of home TPN has been concentrated towards larger, tertiary facilities. The use of standardised inpatient screening tools has increased from 80% in 2003 to 100% in 2012. Screening of outpatients in acute hospitals has increased from 15% in 2003 to 33% in 2012. <h3>Conclusion</h3> Nutrition service provision has evolved beyond recognition over the last 9 years in the North East. Significant progress has been made in forming focused Nutrition Support Teams, expanding TPN delivery and detecting malnutrition, particularly among the inpatient population. Areas for improvement include the development and promotion of efficient and practical methods to screen outpatients for malnutrition. Ultimately, it is hoped that we can demonstrate our developments have had a significant and sustained impact upon patient care and outcomes. <h3>Disclosure of Interest</h3> None Declared. <h3>Reference</h3> Nutrition support in adults (CG32): 2006 NICE guideline
Abstract 3829: Inducible silencing of PKD3 reveals a critical role for PKD3 in prostate cancer growth and metastasis
Authors: Courtney R. LaValle, Liyong Zhang, Julie Eiseman, Q. Jane Wang
Journal: Cancer Research (2011)

Abstract Protein kinase D is a family of novel serine/threonine kinases that act as major mediators of several signaling pathways related to cancer development. Increasing evidence has demonstrated that specific PKD isoforms are deregulated in human cancers and that PKD plays an active role in cancer cell proliferation, migration, and invasion. Here, we present evidence on the development of a PC3 tetracycline-inducible PKD3 knockdown prostate cancer cell line and its application in both the study of PKD3 function in cells and the validation of PKD3 as a therapeutic target in vivo. We show that tetracycline treatment results in &amp;gt;50% knockdown of endogenous PKD3 expression in two distinct clones expressing PKD3 shRNA (shPKD3-C7 and shPKD3-C26), but has no effect on cells expressing scrambled shRNA (shSCR). Furthermore, endogenous PKD1 or PKD2 expression levels are not altered in PKD3 knockdown cells treated with tetracycline, supporting the specific targeting of the shRNA to the PKD3 isoform. Phenotypic analysis revealed that, similar to studies utilizing PKD siRNAs or novel PKD inhibitors, tetracycline-induced silencing of PKD3 causes potent arrest in cell growth and motility. Additionally, we found that conditioned media collected from tetracycline-treated shPKD3-C7 cells causes a reduction in PC3 cell migration, and we observed increased secretion of the tissue inhibitor of metalloproteinases-2 (TIMP-2) protein, which has important anti-angiogenic functions, from tetracycline-treated shPKD3-C7 cells. Western blotting revealed that both siRNA-mediated transient knockdown of PKD2 or PKD3 or treatment with novel PKD inhibitors led to decreased levels of the matrix metalloproteinases MMP-9, MMP-11, and MMP-14 in PC3 cells. Finally, we found that reduction of PKD3 expression by tetracycline-inducible shRNA significantly retarded both tumor growth in a subcutaneous xenograft model as well as tumor growth and metastasis in an orthotopic prostate cancer xenograft model. Taken together, these data suggest that PKD is a critical signaling protein that modulates prostate cancer cell growth and motility through a pathway involving multiple secreted factors, and that PKD3 is a potential therapeutic target in the treatment of prostate cancer. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 3829. doi:10.1158/1538-7445.AM2011-3829
PTU-070 Selecting the most Cost-Effective Model of Care for Delivering Biological Agents as Maintenance Therapy in Patients with Crohn’S Disease
Authors: E Lougher, M C Allison, K Hodson, M Pugh
Journal: Gut (2013)

<h3>Introduction</h3> The introduction of anti-TNF alpha monoclonal antibodies in 1999 has revolutionised the management of inflammatory bowel disease (IBD). A significant increase in gross spend on biological agents in the management of Crohn’s disease has occurred since the implementation of NICE guidance in 2002. The unplanned nature of the service expansion and evolution has led to a wide variation in service delivery. Within the Aneurin Bevan Local Health Board (ABHB) the approximate doubling in the gastroenterology spend on biologics (between 2010 and 2011) prompted a review of current services and an investigation of other potential models of care for delivering the service. <h3>Methods</h3> A service evaluation for both adalimumab and infliximab (IFX) including: an assessment of the current services from a patient’s perspective (study 1), identifying and exploring models of care for delivering the service (study 2) and evaluating the costs associated with each model of care (study 3) was undertaken. Study 1 comprised face-to-face semi-structured, tape recorded patient-interviews, which were transcribed verbatim and then thematically analysed. Study 2 utilised a number of methods to identify key-informants at various secondary care sites to participate in telephone semi-structured interviews, models identified were compared and contrasted. Study 3 identified and compared the costs of current models within ABHB with viable models identified in study 2. <h3>Results</h3> The results revealed overall satisfaction with the IBD services within ABHB and with the service provided by Healthcare at Home Ltd. Patients were complementary of the IBD team and the telephone help line. Nonetheless areas for improvement with regards to the infusion facilities were identified by the IFX group. Study 3 identified four models of care: IFX prepared in pharmacy, IFX prepared by a specialist nurse, IFX at home and adalimumab at home. For standard dosing (79kg patient-average IFX patient weight at ABHB) annual costs were £12,237, £12,314, £10,254 and £9,156 respectively, inclusive of pharmacy production time, nursing time and active drug and exclusive of hospital facilities. Vial sharing would reduce the cost of models one and two, however would require complex re-organisation to facilitate “pairing” patients. Study 3 identified adalimumab via Healthcare at Home as being the most cost-effective model. <h3>Conclusion</h3> Where clinically appropriate adalimumab via Healthcare at Home Ltd is recommended for this group of patients within ABHB, with IFX via a home care company as second line. Work should be done to improve the current infusion facilities. Future work should include reviewing the potential of setting up a biologics unit shared between specialities. <h3>Disclosure of Interest</h3> None Declared
Abstract 5329A: Micro-CT enables microlocalization and quantification of Her2-targeted gold nanoparticles within tumor regions
Authors: James F. Hainfeld, Michael J. O'Connor, Avraham Dilmanian, Daniel N. Slatkin, Douglas J. Adams, Henry M. Smilowitz
Journal: Cancer Research (2011)

Abstract Gold nanoparticles are of interest as potential in vivo diagnostic and therapeutic agents, as X-ray contrast agents, drug delivery vehicles and radiation enhancers. The aim of this study was to quantitatively determine their targeting and microlocalization in mouse tumor models after intravenous injection by using micro- CT. Gold nanoparticles (15 nm) were coated with polyethylene glycol and covalently coupled to anti-Her2 antibodies (Herceptin). In vitro, conjugates incubated with Her2+ (BT-474) and Her2- (MCF7) human breast cancer cells showed specific targeted binding with a Her2+ to Her2- gold ratio of 39.4± 2.7:1. Nude mice, simultaneously bearing subcutaneous Her2+ and Her2- human breast tumors in opposite thighs were prepared. Gold nanoparticles alone, conjugated to Herceptin or to a non-specific antibody were compared. After intravenous injection of the gold nanoparticles, gold concentrations were determined by atomic absorption spectroscopy. Microlocalization of gold was carried out by calibrated micro-CT, giving both the radiodensities and gold concentrations in tumor and non-tumor tissue. All gold nanoparticle constructs showed accumulation, predominantly at tumor peripheries. However, the Herceptin-gold nanoparticles showed the best specific uptake in their periphery (15.8± 1.7% injected dose g-1), 1.6-fold higher than Her2- tumors and 22-fold higher than surrounding muscle. Imaging readily enabled detection of small, 1.5-mm-thick tumors. In this pre-clinical study, antibody-targeted 15 nm gold nanoparticles showed preferential uptake in cognate tumors, but even untargeted gold nanoparticles enhanced the visibility of tumor peripheries and enabled detection of millimeter-sized tumors. Micro-CT enabled quantification within various regions of a tumor. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 5329A. doi:10.1158/1538-7445.AM2011-5329A
Large-bowel obstruction caused by pancreatic tail cancer
Authors: K. Izuishi, T. Sano, Y. Okamoto, H. Mori, M. Oryu, T. Maeta, K. Ebara
Journal: Endoscopy (2012)

A 60-year-old man presented to our hospital with abdominal pain. Enhanced abdominal computed tomography (CT) revealed a well-demarcated, low-density tumor in the tail of the pancreas ([Fig. 1]). 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) showed high uptake in the tumor (standardized uptake value 17) ([Fig. 2]). Colonoscopy revealed a mass in the descending colon causing marked stenosis ([Fig. 3]). Consistent with this finding, the colonoscope could not pass through the obstructed segment. CT colonography revealed an apple-core lesion in the descending colon ([Fig. 4]), and histological examination of the biopsy samples revealed poorly differentiated adenocarcinoma. A few days later, the patient was admitted with abdominal pain due to acute large-bowel obstruction. Emergency distal pancreatectomy, left hemicolectomy, and partial adrenalectomy and lymph node dissection were carried out. Gross examination of the resected specimen showed a submucosal tumor of the colon with the majority of the tumor residing in the pancreas ([Fig. 5]). The patient was diagnosed as having anaplastic pancreatic cancer with osteoclast-like giant cells. Postoperative follow-up at 2 years showed no recurrence.
The Expression of CRTh2 on Blood Basophils and Eosinophils in Chronic Idiopathic Urticaria
Authors: Eric Oliver, Patricia M. Sterba, Sarbjit S. Saini, Becky M. Vonakis, Kelly Devine
Journal: Journal of Allergy and Clinical Immunology (2015)

Evidence of mast cell (MC) degranulation and infiltration by leukocytes such as basophils, eosinophils, and T lymphocytes is observed in lesions in chronic idiopathic urticaria (CIU). Since activated MCs release Prostaglandin D2 (PGD2), a possible recruitment pathway for these leukocytes is CRTh2, a receptor for PGD2. We compared CRTh2 expression on leukocytes in the blood of CIU and healthy subjects. We recruited adult CIU subjects (n=20) and nonatopic subjects (n=8) and examined basal expression of CRTH2 via flow cytometry. Basophils and eosinophils were gated using scatter and specific markers. Values are reported as Median Net MFI (± SEM). Data were analyzed using Mann-Whitney Test. CRTh2 expression was significantly decreased on basophils from CIU subjects as compared with healthy controls (307.1 ± 21.11 vs 398.4 ± 29.41, p=0.0395). CRTh2 surface expression on eosinophils from CIU subjects also trended lower as compared to controls (61.18 ± 4.197 vs 70.88 ± 6.77, p=0.0524). CRTh2 expression levels were more variable on basophils and eosinophils in CIU subjects as compared to controls. There was no difference between the percentage of basophils or eosinophils expressing CRTh2 in CIU compared with controls. CRTh2 expression on leukocytes from CIU subjects is more variable than healthy controls. Levels on blood basophils are significantly reduced, compared to nonatopic controls. Eosinophil CRTh2 levels were overall lower than basophils and trended lower in CIU subjects. These findings suggest that the CRTh2 pathway may be engaged in the recruitment of eosinophils and basophils to CIU lesions.
Radioimmunoscintigraphy in Patients with Ocular Melanoma
Authors: SONJA BORISSOVA SERGIEVA, ASSENETA VIRTCHEVA-GENKOVA
Journal: Clinical Nuclear Medicine (1997)

The aim of this study was to determine the usefulness of radioimmunoscintigraphy (RIS) with monoclonal antibodies (MAb) to detect primary ocular melanoma and its relapses and metastases. The authors studied nineteen patients (9 men and 10 women), aged 24 to 74 who were suspected of having ocular pigmented tumors by means of RIS. The authors used F(ad)2-fragments of monoclonal antibodies against high molecular weight-melanoma associated antigen, labeled with Tc-99m (activity 370-555 MBq). Planar and SPECT imaging were performed at 6, 12, and 24 hours. The sensitivity of the method was 78.6%; the specificity was 100%; and the accuracy was 84.2%. The results obtained suggest that RIS is a highly specific and sensitive technique in the differential diagnosis of malignant ocular melanoma.
Stat Bite: Colorectal Cancer Survival
Authors: L. A.G. Ries
Journal: JNCI Journal of the National Cancer Institute (1994)

Journal Article Stat Bite: Colorectal Cancer Survival Get access Lynn A.G. Ries Lynn A.G. Ries Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 86, Issue 6, 16 March 1994, Page 415, https://doi.org/10.1093/jnci/86.6.415 Published: 16 March 1994
Prognostic factors for long term survival in patients with metastatic sarcoma; the view from a single centre
Authors: M. Scurr, O. Al-Muderis, A. Karup-Hansen, C. Harmer, C. Fisher, J. M. Thomas, I. Judson
Journal: Journal of Clinical Oncology (2005)

9022 Background: Median survival after diagnosis of metastases in sarcoma is < 1yr, but ∼10% survive >5 years. Previous studies have used specific patient cohorts that may not be reflective of a general sarcoma practice, thus this study was performed to determine factors predictive of long term survival in unselected metastatic sarcoma patients seen at a large sarcoma unit, with a subset analysis of adult soft tissue sarcoma patients. Methods: A retrospective review of the Royal Marsden Hospital Sarcoma database of all sarcoma patients (pts) who developed metastatic disease before 30 November 1999 was undertaken and variables including age, histology, size and grade of primary, stage at diagnosis, time to 1st metastatic relapse, sites and number of metastases, and treatment were compared. Pts lost to follow up were excluded. A subgroup analysis of adults (≥16yrs) with soft tissue sarcoma was also performed. Results 919 pts who developed metastatic sarcoma before 30 November 1999 were reviewed. Multivariate analysis showed that independent variables for poorer survival were higher grade (p<0.005), older age P<0.001), shorter time to 1st relapse (p<0.001) and presence of extrapulmonary metastases (p<0.001). 611 adults had metastatic soft tissue sarcoma, 106 (17.3%) survived ≥ 5yrs. Median survival after development of metastases was 14 mos (range; 1–400 mos), for those that survived ≥ 5yrs the median survival was 91.5 mos. Significant variables predictive of long term survival include time to relapse, initial stage, grade, and histological subtype; leiomyosarcoma, synovial sarcoma, MFH, angiosarcoma, and GIST being especially poor. Conclusions: This study aimed to determine prognostic survival variables for metastatic sarcoma irrespective of therapy. Age, as well as variables reflecting tumour biology such as grade, and time to 1st relapse were found to be important. For adult soft tissue sarcoma patients, histological subtype was also significant. Survival with metastatic sarcoma would appear to be dependent on the biology of the primary and preliminary analysis also indicated that response to chemotherapy and metastatectomy also played a key role. No significant financial relationships to disclose.